Saltar al contenido
Merck
Todas las fotos(1)

Documentos

SRP4693

Sigma-Aldrich

Apolipoprotein A−I human

recombinant, expressed in E. coli, ≥97% (SDS-PAGE), ≥97% (HPLC)

Sinónimos:

APOA1, Apo-AI, Apolipoprotein A-I, C117399, MGC117399

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Número de CAS:
Código UNSPSC:
12352202
NACRES:
NA.32

origen biológico

human

recombinante

expressed in E. coli

Análisis

≥97% (HPLC)
≥97% (SDS-PAGE)

formulario

lyophilized

mol peso

~28 kDa

envase

pkg of 100 μg

condiciones de almacenamiento

avoid repeated freeze/thaw cycles

impurezas

endotoxin, tested

Nº de acceso NCBI

Nº de acceso UniProt

Condiciones de envío

wet ice

temp. de almacenamiento

−20°C

Información sobre el gen

human ... ApoA1(335)

¿Está buscando productos similares? Visita Guía de comparación de productos

Descripción general

ApoA-I (apolipoprotein A-I) is a 29.0kDa protein produced in the liver and intestine, and secreted as the predominant constituent of nascent high-density lipoprotein (HDL) particle. Recombinant human ApoA-I is a 28.2kDa protein of 244 amino acid residues.
ApoA-I, which is found exclusively in HDL, has a unique ability to capture and solubilize free cholesterol. This apoA-I ability enables HDL to remove excess peripheral cholesterol and return it to the liver for recycling and excretion. This process, called reverse cholesterol transport, is though to inhibit atherogenesis. For this reason HDL is also known as the "good cholesterol." The therapeutic potential of apoA-I has been recently assessed in patients with acute coronary syndromes, using a recombinant form of a naturally occurring variant of apoA-I (called apoA-I Milano). The availability of recombinant normal apoA-I should facilitate further investigation into the potential usefulness of apoA-I in preventing atherosclerotic vascular diseases.

Aplicación

Apolipoprotein A-I human has been used in the cholesterol efflux assay.

Acciones bioquímicas o fisiológicas

ApoA-I (apolipoprotein A-I), which is found exclusively in HDL (high-density lipoprotein), has a unique ability to capture and solubilize free cholesterol. This apoA-I ability enables HDL to remove excess peripheral cholesterol and return it to the liver for recycling and excretion. This process, called reverse cholesterol transport, is thought to inhibit atherogenesis. For this reason HDL is also known as the "good cholesterol." The therapeutic potential of apoA-I has been recently assessed in patients with acute coronary syndromes, using a recombinant form of a naturally occurring variant of apoA-I (called apoA-I Milano). The availability of recombinant normal apoA-I should facilitate further investigation into the potential usefulness of apoA-I in preventing atherosclerotic vascular diseases. Changes in the level of serum apoA-I may serve as a prognostic marker for non-metastatic nasopharyngeal carcinoma. Low levels of apoA-I in the plasma is linked to hyperhomocysteinemia.

Forma física

Sterile filtered and Lyophilized without additives.

Nota de preparación

Centrifuge the vial prior to opening. Avoid freeze-thaw cycles.

Reconstitución

Reconstitute in water to a concentration of 0.1-1.0 mg/ml. The solution can then be diluted into other aqueous buffers and store at 4 °C for 1 week or –20 °C for future use.

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I.
Timmins JM
The Journal of Clinical Investigation, 115, 1333-1342 (2005)
Serum apolipoprotein A-I is a novel prognostic indicator for non-metastatic nasopharyngeal carcinoma.
Luo XL, et al.
Oncotarget, 6, 44037-44048 (2015)
ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I.
Gelissen IC
Arteriosclerosis, Thrombosis, and Vascular Biology, 26, 534-540 (2006)
Huairui Shi et al.
Scientific reports, 6, 20154-20154 (2016-01-30)
Lanatoside C's impact on atherosclerosis is poorly understood. The present study was conducted to determine whether lanatoside C affects the development of atherosclerosis in apolipoprotein E-deficient (ApoE(-/-)) mice. ApoE(-/-) mice were administered either phosphate-buffered saline (PBS) containing 0.1% DMSO (the
Somatic gene transfer of human ApoA-I inhibits atherosclerosis progression in mouse models.
Benoit P, et al.
Circulation, 99, 105-110 (1999)

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico